恩利文治療公司
US ˙ NasdaqGS ˙ US29337E1029

SecurityELVN / Enliven Therapeutics, Inc.
InstitutionInvesco Ltd.
Latest Disclosed Ownership61,752 shares
Latest Disclosed Value $ 2,420,678
Invesco Ltd. reports 149.81% increase in ownership of ELVN / Enliven Therapeutics, Inc.

On May 12, 2026 - Invesco Ltd. filed a 13F-HR form disclosing ownership of 61,752 shares of Enliven Therapeutics, Inc. (US:ELVN) valued at $2,420,678 USD as of March 31, 2026. The entity filed a previous 13F-HR on February 19, 2026 disclosing 24,720 shares of Enliven Therapeutics, Inc.. This represents a change in shares of 149.81% during the quarter. The current value of the position is $2,191,578 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2026-05-12 2026-03-31 13F ENLIVEN THERAPEUTICS COM 29337E102 61,752 37,032 149.81 2,421 536.84 0.0000
2026-02-19 2025-12-31 13F ENLIVEN THERAPEUTICS COM 29337E102 24,720 1,624 7.03 381 -19.49 0.0001
2025-11-13 2025-09-30 13F ENLIVEN THERAPEUTICS COM 29337E102 23,096 1,139 5.19 473 7.27 0.0001
2025-08-13 2025-06-30 13F ENLIVEN THERAPEUTICS COM 29337E102 21,957 913 4.34 440 6.28 0.0001
2025-05-12 2025-03-31 13F ENLIVEN THERAPEUTICS COM 29337E102 21,044 5,972 39.62 414 22.12 0.0001
2025-02-13 2024-12-31 13F ENLIVEN THERAPEUTICS COM 29337E102 15,072 508 3.49 339 -8.63 0.0001
2024-11-12 2024-09-30 13F ENLIVEN THERAPEUTICS COM 29337E102 14,564 264 1.85 372 11.08 0.0001
2024-08-13 2024-06-30 13F ENLIVEN THERAPEUTICS COM 29337E102 14,300 1,811 14.50 334 52.51 0.0001
2024-05-14 2024-03-31 13F ENLIVEN THERAPEUTICS COM 29337E102 12,489 1 0.01 220 27.33 0.0000
2024-02-13 2023-12-31 13F ENLIVEN THERAPEUTICS COM 29337E102 12,488 -6,278 -33.45 173 -32.81 0.0000
2023-11-13 2023-09-30 13F ENLIVEN THERAPEUTICS COM 29337E102 18,766 18,766 256 0.0001
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.